ExozymesEXOZ
13F holders, Q1 2026 (March 31)7holders
0new positions
1sold out
$7.50avg. 13F price*
At the end of Q1 2026, 7 institutions reported holding Exozymes Inc. (EXOZ) in their 13F filings, unchanged from Q4 2025. 0 opened new positions and 1 sold out. The largest holders were Vanguard Capital Management LLC ($166K), Geode Capital Management, LLC ($164K) and Vanguard Fiduciary Trust Co. ($71K).
- Company
- Exozymes Inc.
- CUSIP
- 461874109
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q4 2025 → Q1 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 1 | $185 |
All 13F filers, Q4 2025 → Q1 2026: 1,882 shares bought and 1,688 shares sold, net +194 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 7 holders
| Vanguard Capital Management LLC | 0.00% | — | 22,190 | $166K |
| Geode Capital Management, LLC | 0.00% | Reduce -7.1% | 21,891 | $164K |
| Vanguard Fiduciary Trust Co. | 0.00% | — | 9,426 | $71K |
| BlackRock, Inc. | 0.00% | Add +8.7% | 6,797 | $51K |
| Tower Research Capital LLC (TRC) | 0.00% | Add +65750.0% | 1,317 | $10K |
| Morgan Stanley | 0.00% | No change | 1,250 | $9K |
| UBS Group AG | 0.00% | Add +700.0% | 24 | $180 |
"% of holder's portfolio" is EXOZ's weight in each manager's 13F, not the share of Exozymes Inc. the manager owns.